Inclusion Criteria:

          -  Has histologically or cytologically confirmed melanoma

          -  Has unresectable Stage III or Stage IV melanoma, not amenable to local therapy

          -  Has progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb)
             administered either as monotherapy, or in combination with other therapies

          -  Has submitted prestudy imaging

          -  Has not received more than 3 lines of therapy for their advanced melanoma

          -  Has provided a tumor biopsy

          -  Male participants who receive lenvatinib are abstinent from heterosexual intercourse
             or agree to use contraception during the intervention period and for at least 7 days
             after the last dose of lenvatinib; for male participants who only receive
             pembrolizumab, quavonlimab, vibostolimab, or a combination, no contraception measures
             are needed

          -  Female participant are not pregnant or breastfeeding and are either not a woman of
             child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective
             or are abstinent from heterosexual intercourse during the intervention period and for
             at least 120 days after the last dose of pembrolizumab, quavonlimab, vibostolimab or
             30 days after the last dose of lenvatinib, whichever occurs last

          -  Has adequate organ function

          -  Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less
             (except alopecia)

        Exclusion Criteria:

          -  Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7
             days before the first dose of study intervention

          -  Has a known additional malignancy that is progressing or requires active treatment
             within the past 2 years

          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Has ocular or mucosal melanoma

          -  Has known hypersensitivity including previous clinically significant hypersensitivity
             reaction to treatment with another mAb

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years

          -  Has an active infection requiring systemic therapy

          -  Has known history of human immunodeficiency virus (HIV)

          -  Has known history of hepatitis B

          -  Has a history of (noninfectious) pneumonitis

          -  Has a history of active tuberculosis (TB)

          -  Has received prior systemic anticancer therapy within 4 weeks prior to randomization

          -  Has received prior radiotherapy within 2 weeks of first dose of study intervention

          -  Has had major surgery <3 weeks prior to first dose of study intervention

          -  Has received a live vaccine within 30 days before the first dose of study intervention

          -  Has participated in a study of an investigational agent within 4 weeks prior to the
             first dose of study intervention

          -  Has had an allogeneic tissue/solid organ transplant

          -  Has a pre-existing Grade ≥3 gastrointestinal fistula or nongastrointestinal fistula

          -  Has radiographic evidence of encasement of invasion of major blood vessel or of
             intratumoral cavitation

          -  Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the
             first dose of study intervention

          -  Has clinically significant cardiovascular disease within 12 months from first dose of
             study intervention